Roivant Sciences Ltd.
ROIV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001635088
In the last 90 days, Roivant Sciences Ltd. insiders filed 0 open-market purchases and 8 sales; 500 institutions reported holding it in 13F filings for Q2 2026, worth $19.7B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Q1 2025 vs. Q4 2024
How the institutions holding Roivant Sciences Ltd. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 320 | 4 | 314 | −2 |
| Shares | 562.6M | 3.06M | 557.6M | −1.88M (−0.3%) |
| Value | $6.65B | $36.2M | $5.63B | −$991.7M (−15.0%) |
4 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (57)
Institutions that held Roivant Sciences Ltd. at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (59)
Institutions that held Roivant Sciences Ltd. at the end of Q4 2024 and filed for Q1 2025 without it.
Not filed for Q1 2025 yet (4)
Institutions that held Roivant Sciences Ltd. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 3,013,533 | $35.7M |
| Corbin Capital Partners, L.P. | 46,641 | $551.8K |
| Global Retirement Partners, LLC | 26 | $308 |
| Cassady Schiller Wealth Management, LLC | 2 | $24 |